A61K 31/739
Lipopolysaccharides
A61K31/739 (Lipopolysaccharides) appears on 172 US grants and 387 published applications in this corpus.
Search patents in A61K- Granted patents
- 172
- Published applications
- 387
- Assignees
- 195
- Inventors
- 607
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1987 | 1 | 0 |
| 1988 | 0 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 0 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 0 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 4 |
| 2003 | 1 | 15 |
| 2004 | 5 | 33 |
| 2005 | 3 | 32 |
| 2006 | 8 | 30 |
| 2007 | 2 | 23 |
| 2008 | 7 | 23 |
| 2009 | 6 | 14 |
| 2010 | 12 | 18 |
| 2011 | 15 | 15 |
| 2012 | 6 | 8 |
| 2013 | 12 | 14 |
| 2014 | 10 | 16 |
| 2015 | 9 | 5 |
| 2016 | 7 | 16 |
| 2017 | 8 | 9 |
| 2018 | 8 | 14 |
| 2019 | 7 | 18 |
| 2020 | 11 | 12 |
| 2021 | 6 | 16 |
| 2022 | 11 | 17 |
| 2023 | 3 | 8 |
| 2024 | 3 | 6 |
| 2025 | 7 | 11 |
| 2026 | 1 | 10 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Immune priming to accelerate/enhance immune response through administration of natural immune modulator1 Sep 2026US 12,721,889 B2ZIVO Bioscience, Inc.
- Extended release immunomodulatory implant to facilitate bone morphogenesis2 Dec 2025US 12,485,011 B2
- Liposomal formulation of bacterial lipopolysaccharide combined with a cytotoxic agent, and use thereof in anti-tumour therapy7 Oct 2025US 12,433,838 B2Centre Leon Berard
- Nanoparticle constructs for systemic co-delivery of anti-tumor agents5 Aug 2025US 12,377,118 B2Case Western Reserve University
- Pegylated liposomes and methods of use3 Jun 2025US 12,318,484 B2Access To Advanced Health Institute
- Lipopolysaccharide, lipopolysaccharide production method, and lipopolysaccharide composition24 Sep 2026US 2026/0286410 A1BioMedical Research Group Inc.
- Nutritional composition for inhibiting survival of rna virus and method for treating rna virus infection20 Aug 2026US 2026/0240943 A1Trade Wind Biotech Co., Ltd.
- Serratia anticancer polysaccharide compositions and methods30 Jul 2026US 2026/0216230 A1
- Algoriphagus sp, bosea sp, brevundimonas sp, desulfovibrio sp, microbacterium sp, sphingomonas sp, and variovorax sp for use in disease prevention and treatment11 Jun 2026US 2026/0158082 A1ZIVO Bioscience, Inc.
- Vaccines30 Apr 2026US 2026/0115280 A1
Most cited
By later US patents
- Immunostimulatory combinations138US 7,387,271 B23M Innovative Properties Company · 2008
- Cancer treatment by combination therapy109US 7,510,830 B2Cancer Research Technology Limited · 2009
- Prevention and treatment of amyloidogenic disease96US 6,972,127 B2Neuralab Limited · 2005
- Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response90US 6,797,276 B1The United States of America as represented by the Secretary of the Army · 2004
- Prevention and treatment of amyloidogenic disease68US 7,014,855 B2Neuralab Limited · 2006